Apo-Risedronate risedronate sodium 150 mg tablets blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

apo-risedronate risedronate sodium 150 mg tablets blister pack

arrotex pharmaceuticals pty ltd - risedronate sodium hemipentahydrate, quantity: 173.4 mg - tablet, film coated - excipient ingredients: hypromellose; magnesium stearate; crospovidone; titanium dioxide; hyprolose; colloidal anhydrous silica; macrogol 8000; lactose; monobasic sodium phosphate dihydrate; dibasic sodium phosphate; indigo carmine aluminium lake; monobasic sodium phosphate monohydrate - the treatment of osteoporosis,the treatment of glucocorticoid-induced osteoporosis,the preservation of bone-mineral density in patients on long term corticosteroid therapy

APO-RISEDRONATE risedronate sodium (as hemipentahydrate) 35 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

apo-risedronate risedronate sodium (as hemipentahydrate) 35 mg tablet blister pack

arrotex pharmaceuticals pty ltd - risedronate sodium hemipentahydrate, quantity: 40.5 mg (equivalent: risedronate sodium, qty 35 mg) - tablet, film coated - excipient ingredients: colloidal anhydrous silica; iron oxide red; macrogol 8000; magnesium stearate; hyprolose; lactose; titanium dioxide; hypromellose; crospovidone; iron oxide yellow - - treatment of osteoporosis. - treatment of glucocorticoid-induced osteoporosis. - preservation of bone mineral density in patients on long term corticosteroid therapy.

Apo-Risedronate risedronate sodium 75mg tablets bottle Australia - English - Department of Health (Therapeutic Goods Administration)

apo-risedronate risedronate sodium 75mg tablets bottle

arrotex pharmaceuticals pty ltd - risedronate sodium hemipentahydrate, quantity: 86.7 mg - tablet, film coated - excipient ingredients: hypromellose; titanium dioxide; macrogol 8000; iron oxide red; colloidal anhydrous silica; hyprolose; magnesium stearate; crospovidone; lactose - the treatment of osteoporosis,the treatment of glucocorticoid-induced osteoporosis,the preservation of bone-mineral density in patients on long term corticosteroid therapy

Apo-Risedronate risedronate sodium 75mg film coated tablets blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

apo-risedronate risedronate sodium 75mg film coated tablets blister pack

arrotex pharmaceuticals pty ltd - risedronate sodium hemipentahydrate, quantity: 86.7 mg - tablet, film coated - excipient ingredients: hyprolose; iron oxide red; colloidal anhydrous silica; magnesium stearate; hypromellose; macrogol 8000; crospovidone; titanium dioxide; lactose - the treatment of osteoporosis,the treatment of glucocorticoid-induced osteoporosis,the preservation of bone-mineral density in patients on long term corticosteroid therapy

APO-RISEDRONATE risedronate sodium (as hemipentahydrate) 35 mg tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

apo-risedronate risedronate sodium (as hemipentahydrate) 35 mg tablet bottle

arrotex pharmaceuticals pty ltd - risedronate sodium hemipentahydrate, quantity: 40.5 mg (equivalent: risedronate sodium, qty 35 mg) - tablet, film coated - excipient ingredients: hypromellose; titanium dioxide; macrogol 8000; lactose; magnesium stearate; iron oxide red; crospovidone; hyprolose; colloidal anhydrous silica; iron oxide yellow - - treatment of osteoporosis. - treatment of glucocorticoid-induced osteoporosis. - preservation of bone mineral density in patients on long term corticosteroid therapy.

RISEDRONATE SODIUM- risedronate sodium tablet, film coated United States - English - NLM (National Library of Medicine)

risedronate sodium- risedronate sodium tablet, film coated

mylan pharmaceuticals inc. - risedronate sodium (unii: ofg5exg60l) (risedronic acid - unii:km2z91756z) - risedronate sodium 5 mg - risedronate sodium tablets are indicated for the treatment and prevention of osteoporosis in postmenopausal women. in postmenopausal women with osteoporosis, risedronate reduces the incidence of vertebral fractures and a composite endpoint of nonvertebral osteoporosis-related fractures [see clinical studies (14.1, 14.2) ]. risedronate sodium tablets are indicated for treatment to increase bone mass in men with osteoporosis. risedronate sodium tablets are indicated for the treatment and prevention of glucocorticoid-induced osteoporosis in men and women who are either initiating or continuing systemic glucocorticoid treatment (daily dosage of greater than or equal to 7.5 mg of prednisone or equivalent) for chronic diseases. patients treated with glucocorticoids should receive adequate amounts of calcium and vitamin d. risedronate sodium tablets are indicated for treatment of paget’s disease of bone in men and women. the optimal duration of use has not been determined. the safety and effectiveness of risedronate

APO-RISEDRONATE TABLET Canada - English - Health Canada

apo-risedronate tablet

apotex inc - risedronate sodium (risedronate sodium hemipentahydrate) - tablet - 150mg - risedronate sodium (risedronate sodium hemipentahydrate) 150mg - bone resorption inhibitors

PMS-RISEDRONATE TABLET Canada - English - Health Canada

pms-risedronate tablet

pharmascience inc - risedronate sodium (risedronate sodium hemipentahydrate) - tablet - 35mg - risedronate sodium (risedronate sodium hemipentahydrate) 35mg - bone resorption inhibitors

APO-RISEDRONATE TABLET Canada - English - Health Canada

apo-risedronate tablet

apotex inc - risedronate sodium (risedronate sodium hemipentahydrate) - tablet - 35mg - risedronate sodium (risedronate sodium hemipentahydrate) 35mg - bone resorption inhibitors

PMS-RISEDRONATE TABLET Canada - English - Health Canada

pms-risedronate tablet

pharmascience inc - risedronate sodium (risedronate sodium hemipentahydrate) - tablet - 150mg - risedronate sodium (risedronate sodium hemipentahydrate) 150mg - bone resorption inhibitors